Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
North Dakota residents who track their GLP-1 progress achieve better outcomes. Whether you are in Adams County or a smaller community, our data-driven telehealth platform lets you monitor milestones, log results, and receive physician-guided dose adjustments based on your actual measured progress — not assumptions.
FDA-approved GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce measurable results: 15-22% average body weight reduction in clinical trials. Our tracking platform helps ND patients see exactly where they stand against these benchmarks and enables physicians to optimize treatment in real time.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
North Dakota telehealth regulations support our data-driven prescribing model. All providers hold active ND medical licenses and conduct structured milestone reviews, using tracked patient data to guide dose adjustments and treatment optimization — ensuring every clinical decision is backed by measurable evidence.
Select your city to access GLP-1 treatment with integrated progress monitoring and milestone tracking throughout North Dakota.
The following landmark trials published in the New England Journal of Medicine establish the efficacy and safety profile of FDA-approved GLP-1 medications:
North Dakota authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in North Dakota.
Our data-driven GLP-1 tracking platform extends to all states neighboring North Dakota and across all 50 states nationwide.
FDA-approved GLP-1 prescriptions are accessible from any city through our board-certified telehealth network. Find your city below to get started.
Local weight loss and GLP-1 providers serving the North Dakota area, based on Google Business listings.
435 32nd Ave E Suite B, West Fargo, ND 58078
(701) 205-3088
5/5 ★ (659 reviews)
Visit website →PLLC, 3501 45th St S Suite B, Fargo, ND 58104
(701) 807-0684
5/5 ★ (5 reviews)
Visit website →4503 Coleman St %23208, Bismarck, ND 58503
(701) 354-0964
5/5 ★ (8 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
After establishing your baseline measurements, you log weekly progress data — weight, measurements, appetite changes, and side effects. Your North Dakota-licensed physician reviews this tracked data at structured intervals to make data-driven dose adjustments and treatment optimizations.
Key milestones include your first 5 lbs lost, 5% body weight reduction (typically months 2-3), 10% reduction (months 4-6), and continued progress toward 15-22% total reduction. Your North Dakota physician sets personalized targets based on your baseline data and health profile.
Clinical trial data for each approved GLP-1 medication provides clear benchmarks: semaglutide −15.3% over 68 weeks (STEP 1), tirzepatide −22.5% over 72 weeks (SURMOUNT-1), liraglutide −8.4% over 56 weeks (SCALE). Your prescribing physician tracks your results against these evidence-based targets.
Patients who track their GLP-1 progress in North Dakota benefit from data-driven care. Their physicians can detect plateaus early, identify optimal dose timing, and make proactive adjustments based on measured trends rather than subjective reports — leading to faster, more consistent weight loss.
Begin with a free baseline assessment — completed online in about 3 minutes. A ND-licensed physician reviews your starting measurements, conducts a telehealth consultation, and establishes your personalized milestone targets if you qualify for GLP-1 treatment.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
